Literature DB >> 17606460

Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.

Mohamad Mohty1, Odile Avinens, Catherine Faucher, Patrice Viens, Didier Blaise, Jean-Francois Eliaou.   

Abstract

This study investigated the kinetics of CD3+-T cell chimerism (TCC) in 102 patients receiving reduced intensity conditioning allogeneic stem cell transplantation (RIC-allo-SCT) from an HLA-identical sibling. Patients with full donor TCC at day 30 had a higher incidence of grade 2-4 acute GVHD compared to patients in mixed TCC (cumulative-incidence, 61% vs. 35%; p=0.01). The delayed establishment of full donor TCC in myeloid malignancies was associated with a higher incidence of relapse (40% vs. 0; p=0.002), suggesting that monitoring of the kinetics of TCC is mandatory after RIC-allo-SCT.

Entities:  

Mesh:

Year:  2007        PMID: 17606460     DOI: 10.3324/haematol.10971

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  18 in total

1.  Quantitative chimerism in CD3-negative mononuclear cells predicts prognosis in acute myeloid leukemia patients after hematopoietic stem cell transplantation.

Authors:  Anne Bouvier; Jérémie Riou; Sylvain Thépot; Aurélien Sutra Del Galy; Sylvie François; Aline Schmidt; Corentin Orvain; Marie-Hélène Estienne; Alban Villate; Damien Luque Paz; Laurane Cottin; Bénédicte Ribourtout; Annaëlle Beucher; Yves Delneste; Norbert Ifrah; Valérie Ugo; Mathilde Hunault-Berger; Odile Blanchet
Journal:  Leukemia       Date:  2019-11-25       Impact factor: 11.528

2.  The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study.

Authors:  Suzanne van Dorp; Henrike Resemann; Liane te Boome; Floor Pietersma; Debbie van Baarle; Frits Gmelig-Meyling; Roel de Weger; Eefke Petersen; Monique Minnema; Henk Lokhorst; Saskia Ebeling; Scott J P Beijn; Edward F Knol; Marijke van Dijk; Ellen Meijer; Jürgen Kuball
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

3.  Kinetics of peripheral blood chimerism for surveillance of patients with leukemia and chronic myeloid malignancies after reduced-intensity conditioning allogeneic hematopoietic SCT.

Authors:  L Eggimann; S Girsberger; J Halter; S Gerull; A Tichelli; H Baldomero; D Heim; J Passweg; A Rovó
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

4.  Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002).

Authors:  Asad Bashey; Kouros Owzar; Jeffrey L Johnson; Peggy S Edwards; Michael Kelly; Lee-Ann Baxter-Lowe; Steven Devine; Sherif Farag; David Hurd; Edward Ball; Philip McCarthy; John Lister; Thomas C Shea; Charles Linker
Journal:  Biol Blood Marrow Transplant       Date:  2010-07-30       Impact factor: 5.742

5.  Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival.

Authors:  John Koreth; Haesook T Kim; Sarah Nikiforow; Edgar L Milford; Philippe Armand; Corey Cutler; Brett Glotzbecker; Vincent T Ho; Joseph H Antin; Robert J Soiffer; Jerome Ritz; Edwin P Alyea
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-04       Impact factor: 5.742

6.  Chimerism status is correlated to acute graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Ying Jiang; Li-ping Wan; You-wen Qin; Xiao-rui Wang; Shi-ke Yan; Kuang-cheng Xie; Chun Wang
Journal:  Int J Hematol       Date:  2014-01-31       Impact factor: 2.490

7.  Preferential depletion of host over donor T cells through in vivo decay of active rabbit-anti-thymocyte globulin levels during reduced intensity conditioning.

Authors:  M Sanacore; X Zhang; S L Brown; K Connor; S Hilton; L E Morris; H K Holland; S R Solomon; A Bashey
Journal:  Bone Marrow Transplant       Date:  2015-03-23       Impact factor: 5.483

8.  Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial.

Authors:  S R Solomon; C A Sizemore; X Zhang; S Brown; H K Holland; L E Morris; A Bashey
Journal:  Bone Marrow Transplant       Date:  2014-05       Impact factor: 5.483

9.  Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning.

Authors:  Ran Reshef; Elizabeth O Hexner; Alison W Loren; Noelle V Frey; Edward A Stadtmauer; Selina M Luger; James K Mangan; Saar I Gill; Pavel Vassilev; Kathryn A Lafferty; Jacqueline Smith; Vivianna M Van Deerlin; Rosemarie Mick; David L Porter
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-10       Impact factor: 5.742

10.  Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation.

Authors:  Tomoaki Ueda; Tetsuo Maeda; Shinsuke Kusakabe; Jiro Fujita; Kentaro Fukushima; Takafumi Yokota; Hirohiko Shibayama; Yoshiaki Tomiyama; Yuzuru Kanakura
Journal:  Int J Hematol       Date:  2018-11-17       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.